vs
Apellis Pharmaceuticals, Inc.（APLS）与COPT DEFENSE PROPERTIES（CDP）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是COPT DEFENSE PROPERTIES的1.0倍（$199.9M vs $197.4M），COPT DEFENSE PROPERTIES净利率更高（20.0% vs -29.5%，领先49.5%），COPT DEFENSE PROPERTIES同比增速更快（7.6% vs -5.9%），COPT DEFENSE PROPERTIES自由现金流更多（$288.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
COPT Defense Properties是一家专业房地产投资信托基金，重点投资写字楼物业，资产主要布局于华盛顿大都会区的近郊区域，核心租户为美国政府及国防军工行业企业。截至2024年12月31日，公司旗下共持有164栋写字楼，总面积达1650万平方英尺，同时运营31个单租户数据中心，总面积590万平方英尺。
APLS vs CDP — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $197.4M |
| 净利润 | $-59.0M | $39.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 19.9% |
| 净利率 | -29.5% | 20.0% |
| 营收同比 | -5.9% | 7.6% |
| 净利润同比 | -62.2% | 8.0% |
| 每股收益（稀释后） | $-0.40 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $197.4M | ||
| Q3 25 | $458.6M | $188.8M | ||
| Q2 25 | $178.5M | $189.9M | ||
| Q1 25 | $166.8M | $187.9M | ||
| Q4 24 | $212.5M | $183.4M | ||
| Q3 24 | $196.8M | $189.2M | ||
| Q2 24 | $199.7M | $187.3M | ||
| Q1 24 | $172.3M | $193.3M |
| Q4 25 | $-59.0M | $39.4M | ||
| Q3 25 | $215.7M | $43.7M | ||
| Q2 25 | $-42.2M | $40.2M | ||
| Q1 25 | $-92.2M | $36.2M | ||
| Q4 24 | $-36.4M | $36.5M | ||
| Q3 24 | $-57.4M | $37.4M | ||
| Q2 24 | $-37.7M | $36.4M | ||
| Q1 24 | $-66.4M | $33.7M |
| Q4 25 | -25.6% | 19.9% | ||
| Q3 25 | 48.7% | 22.5% | ||
| Q2 25 | -18.6% | 21.0% | ||
| Q1 25 | -50.0% | 19.1% | ||
| Q4 24 | -12.3% | 19.7% | ||
| Q3 24 | -24.0% | 19.8% | ||
| Q2 24 | -14.7% | 19.4% | ||
| Q1 24 | -36.0% | 17.5% |
| Q4 25 | -29.5% | 20.0% | ||
| Q3 25 | 47.0% | 23.2% | ||
| Q2 25 | -23.6% | 21.1% | ||
| Q1 25 | -55.3% | 19.3% | ||
| Q4 24 | -17.1% | 19.9% | ||
| Q3 24 | -29.2% | 19.8% | ||
| Q2 24 | -18.9% | 19.4% | ||
| Q1 24 | -38.5% | 17.4% |
| Q4 25 | $-0.40 | $0.32 | ||
| Q3 25 | $1.67 | $0.37 | ||
| Q2 25 | $-0.33 | $0.34 | ||
| Q1 25 | $-0.74 | $0.31 | ||
| Q4 24 | $-0.30 | $0.31 | ||
| Q3 24 | $-0.46 | $0.32 | ||
| Q2 24 | $-0.30 | $0.31 | ||
| Q1 24 | $-0.54 | $0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $275.0M |
| 总债务越低越好 | — | $2.8B |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $4.7B |
| 负债/权益比越低杠杆越低 | — | 1.83× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $275.0M | ||
| Q3 25 | $479.2M | $23.7M | ||
| Q2 25 | $370.0M | $21.3M | ||
| Q1 25 | $358.4M | $24.3M | ||
| Q4 24 | $411.3M | $38.3M | ||
| Q3 24 | $396.9M | $34.5M | ||
| Q2 24 | $360.1M | $100.4M | ||
| Q1 24 | $325.9M | $123.1M |
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.4B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | $93.1M | $2.4B |
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $1.5B | ||
| Q3 24 | $237.1M | $1.5B | ||
| Q2 24 | $264.3M | $1.5B | ||
| Q1 24 | $266.7M | $1.5B |
| Q4 25 | $1.1B | $4.7B | ||
| Q3 25 | $1.1B | $4.4B | ||
| Q2 25 | $821.4M | $4.3B | ||
| Q1 25 | $807.3M | $4.3B | ||
| Q4 24 | $885.1M | $4.3B | ||
| Q3 24 | $901.9M | $4.2B | ||
| Q2 24 | $904.5M | $4.2B | ||
| Q1 24 | $831.9M | $4.2B |
| Q4 25 | — | 1.83× | ||
| Q3 25 | — | 1.62× | ||
| Q2 25 | — | 1.63× | ||
| Q1 25 | — | 1.62× | ||
| Q4 24 | — | 1.60× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | 0.35× | 1.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $309.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $288.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 146.4% |
| 资本支出强度资本支出/营收 | 0.1% | 10.7% |
| 现金转化率经营现金流/净利润 | — | 7.87× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $501.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $309.9M | ||
| Q3 25 | $108.5M | $68.6M | ||
| Q2 25 | $4.4M | $87.9M | ||
| Q1 25 | $-53.4M | $72.1M | ||
| Q4 24 | $19.4M | $331.0M | ||
| Q3 24 | $34.1M | $65.1M | ||
| Q2 24 | $-8.3M | $93.8M | ||
| Q1 24 | $-133.0M | $71.0M |
| Q4 25 | $-14.3M | $288.9M | ||
| Q3 25 | $108.3M | $62.9M | ||
| Q2 25 | $4.4M | $84.5M | ||
| Q1 25 | $-53.4M | $65.1M | ||
| Q4 24 | $19.3M | $299.6M | ||
| Q3 24 | — | $61.0M | ||
| Q2 24 | $-8.4M | $88.4M | ||
| Q1 24 | $-133.3M | $57.9M |
| Q4 25 | -7.1% | 146.4% | ||
| Q3 25 | 23.6% | 33.3% | ||
| Q2 25 | 2.5% | 44.5% | ||
| Q1 25 | -32.0% | 34.7% | ||
| Q4 24 | 9.1% | 163.3% | ||
| Q3 24 | — | 32.3% | ||
| Q2 24 | -4.2% | 47.2% | ||
| Q1 24 | -77.3% | 30.0% |
| Q4 25 | 0.1% | 10.7% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 3.7% | ||
| Q4 24 | 0.0% | 17.1% | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.0% | 2.9% | ||
| Q1 24 | 0.2% | 6.8% |
| Q4 25 | — | 7.87× | ||
| Q3 25 | 0.50× | 1.57× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 9.08× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 2.58× | ||
| Q1 24 | — | 2.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CDP
暂无分部数据
